Lupin obtains USFDA EIR for unit 3 of the Pithampur facility
Date: 2018-12-12   Author: Pankaj Singh  Category: #news

Lupin obtains USFDA EIR for unit 3 of the Pithampur facility

Lupin Limited, a transnational pharmaceutical company based in Mumbai, has reportedly received an Establishment Inspection Report (EIR) from the U.S. regulator for the unit 3 of the facility in Madhya Pradesh.

As per sources familiar with the knowledge of the matter, the unit 3 of Pithampur facility was inspected from June 12 till June 16, in the year 2017. Lupin also mentioned in a BSE filing that this was a pre-approval inspection of a product known as Albuterol Sulfate Inhalation.

Nilesh Gupta, Managing Director, Lupin Limited, said that receiving the Establishment Inspection Report (EIR) for the Pithampur unit 3 facility is a rather motivating development. He also added that this is indeed a proof of their commitment to maintain the highest standards in compliance and quality across their facilities.

For the record, the U.S. Food and Drug Administration (USFDA) issues an Establishment Inspection Report (EIR) to the facility that is the subject of a USFDA or inspection by an FDA-contracted agency when they decide to close the inspection. Establishment Inspection Report (EIR) is the term given by the U.S. Food and Drug Administration (USFDA) for the whole narration of what the FDA investigator or inspector did throughout the time spent in the establishment (i.e. a facility), from the period of introduction till the delivery of the inspectional observations.

Incidentally, the week before Lupin announced the completion of USFDA inspections at its Mandideep location that plays host to the company's Cephalosporin Solid Oral Dosage Form facility, and Cephalosporin and Cardiovascular Pril API facilities. The inspections took place from November 26 till December 4, 2018.

Ironically, despite receiving the EIR from the FDA, Lupin’s stock was trading at Rs 824.15 on BSE, down 1.88 percent from its previous close.

For the record, the company manufactures dry powder inhalers, dermatological products, and metered dose inhalers.



About Author


Pankaj Singh

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More from Pankaj


Post Recommendents

Cloud VPN Market Set to Register healthy CAGR During 2020-2025
Author: Ashwin Naphade

This research report Added by Market Study Report, LLC, about the ' Cloud VPN market' provides concise details on the market’s regional spectrum, industry size, and profit forecast. Besid...


Unexpected Growth Seen in Legal Analytics Market from 2020 to 2025
Author: Ashwin Naphade

The newest report on ' Legal Analytics market' now available a MarketStudyReport.com, offers concise facts about the geographical landscape, industry size and revenue estimation of the business. Additionally, the report focuses on challeng...


Crop Reinsurance Market Analysis, Trends, Top Manufacturers, Share, Growth, Statistics, Opportunities & Forecast to 2025
Author: Ashwin Naphade

The ' Crop Reinsurance Market' research report added by Market Study Report, LLC, delivers a comprehensive analysis on the newest market drivers. The report also offers extracts regarding statistics, market valuation and revenue estimates,...